History of HIV Testing in the United States
In 1985, the United States Food and Drug Administration (FDA) licensed the first HIV antibody test for the detection of HIV (Figure 1).[1] Two years later, in 1987, the United States Public Health Service issued recommendations for HIV testing of individuals with a high risk of acquiring HIV, mainly persons with a history of sexually transmitted infections and those who inject drugs; the 1987 recommendations included information regarding counseling, consent, and confidentiality.[2] The 1987 HIV testing recommendations were broadened in 1993 to include HIV testing of hospitalized patients, persons seen in acute care, and persons in emergency room settings.[3] Based on data that emerged showing antiretroviral therapy given to pregnant women with HIV markedly reduced perinatal HIV transmission, the CDC expanded HIV testing guidelines in 2001 and recommended routine HIV testing of all pregnant people.[4] In 2003, the CDC shifted from high-risk HIV testing to a new strategy of making HIV testing a routine part of medical care.[5] The 2003 recommendations served as a transition to the 2006 CDC recommendations to perform routine HIV screening for all persons 13 through 64 years of age in all health care settings.[6] Despite the 2006 recommendations, the CDC estimates that from 2006 through 2016, only 39.6% of noninstitutionalized adults in the United States had ever undergone a test for HIV.[7]
Definitions
The CDC has generated definitions related to HIV screening and testing.[6] These definitions are listed as follows:
- HIV Screening: Performing an HIV test for persons in a defined population.
- HIV Diagnostic Testing: Performing an HIV test for persons with clinical signs or symptoms consistent with HIV.
- Targeted Testing: Performing an HIV test for subpopulations of persons at higher risk, typically defined on the basis of behavioral, clinical, or demographic characteristics.
- Informed Consent: A process of communication between patient and provider through which an informed patient can choose whether to undergo HIV testing or decline to do so. Elements of informed consent typically include providing oral or written information regarding HIV, the risks and benefits of testing, the implications of HIV test results, how test results will be communicated, and the opportunity to ask questions.
- Opt-out Screening: Performing HIV screening after notifying the patient the test will be performed and providing the patient the opportunity to decline or defer testing. Assent is inferred unless the patient declines testing.
- HIV Prevention Counseling: An interactive process of assessing risk, recognizing specific behaviors that increase the risk for acquiring or transmitting HIV, and developing a plan to take specific steps to reduce risks.
Goals of Routine Screening
Identifying persons with HIV is the first step in the HIV care continuum. The primary desired outcomes associated with routine HIV screening are two-fold: (1) improve survival and quality of life for the person with HIV, and (2) prevent the person with HIV from transmitting HIV to others (Figure 2). Persons who have acquired HIV but have not yet been diagnosed, cannot obtain the benefits of modern antiretroviral therapy while they remain undiagnosed.